Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fluorescence-optical imaging as a promising easy-to-use imaging biomarker to increase early psoriatic arthritis detection in patients with psoriasis: a cross-sectional cohort study with follow-up.
Koehm M, Ohrndorf S, Foldenauer AC, Rossmanith T, Backhaus M, Werner SG, Burmester GR, Wassenberg S, Koehler B, Burkhardt H, Behrens F. Koehm M, et al. Among authors: foldenauer ac. RMD Open. 2022 Dec;8(2):e002682. doi: 10.1136/rmdopen-2022-002682. RMD Open. 2022. PMID: 36597973 Free PMC article.
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F; MUST Investigator Group. Koehm M, et al. Among authors: foldenauer ac. Lancet Rheumatol. 2023 Jan;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0. Lancet Rheumatol. 2023. PMID: 38251504 Clinical Trial.
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Koehm M, Foldenauer AC, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester GR, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony HP, Wassenberg S, Burkhardt H, Behrens F. Koehm M, et al. Among authors: foldenauer ac. J Clin Med. 2022 Dec 9;11(24):7316. doi: 10.3390/jcm11247316. J Clin Med. 2022. PMID: 36555933 Free PMC article.
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.
Koehm M, Foldenauer AC, Rossmanith T, Kellner H, Kiltz U, Burmester GR, Kofler DM, Brandt J, Finzel S, Bergner R, Sieburg M, Behrens F; MUST Investigator Group. Koehm M, et al. Among authors: foldenauer ac. RMD Open. 2023 Dec 19;9(4):e003538. doi: 10.1136/rmdopen-2023-003538. RMD Open. 2023. PMID: 38114198 Free PMC article.
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION.
Kloka J, Friedrichson B, Dauth S, Foldenauer AC, Bulczak-Schadendorf A, Vehreschild MJGT, Matos FM, Riera-Mestre A, van Asselt ADI, De Robertis E, Juskeviciene VT, Meybohm P, Tomescu D, Lacombe K, Stehouwer CDA, Zacharowski K; IXION Collaboration Group. Kloka J, et al. Among authors: foldenauer ac. Trials. 2022 Aug 19;23(1):688. doi: 10.1186/s13063-022-06609-x. Trials. 2022. PMID: 35986390 Free PMC article. Clinical Trial.
28 results